Becton, Dickinson and Company (BDX) Competitors

$230.47
-3.36 (-1.44%)
(As of 04/25/2024 ET)

BDX vs. ZTS, MCK, EW, GILD, DXCM, HCA, GSK, COR, IQV, and TAK

Should you be buying Becton, Dickinson and Company stock or one of its competitors? The main competitors of Becton, Dickinson and Company include Zoetis (ZTS), McKesson (MCK), Edwards Lifesciences (EW), Gilead Sciences (GILD), DexCom (DXCM), HCA Healthcare (HCA), GSK (GSK), Cencora (COR), IQVIA (IQV), and Takeda Pharmaceutical (TAK). These companies are all part of the "medical" sector.

Becton, Dickinson and Company vs.

Becton, Dickinson and Company (NYSE:BDX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment.

Becton, Dickinson and Company pays an annual dividend of $3.80 per share and has a dividend yield of 1.6%. Zoetis pays an annual dividend of $1.72 per share and has a dividend yield of 1.1%. Becton, Dickinson and Company pays out 90.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis pays out 33.9% of its earnings in the form of a dividend.

Becton, Dickinson and Company presently has a consensus target price of $280.00, suggesting a potential upside of 21.49%. Zoetis has a consensus target price of $218.00, suggesting a potential upside of 42.15%. Given Zoetis' stronger consensus rating and higher probable upside, analysts clearly believe Zoetis is more favorable than Becton, Dickinson and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Zoetis
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Becton, Dickinson and Company has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

In the previous week, Zoetis had 18 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 25 mentions for Zoetis and 7 mentions for Becton, Dickinson and Company. Becton, Dickinson and Company's average media sentiment score of 0.79 beat Zoetis' score of 0.69 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
13 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Zoetis has lower revenue, but higher earnings than Becton, Dickinson and Company. Zoetis is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$19.37B3.44$1.48B$4.2254.61
Zoetis$8.54B8.21$2.34B$5.0730.25

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 0.3% of Becton, Dickinson and Company shares are owned by insiders. Comparatively, 0.1% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zoetis has a net margin of 27.43% compared to Becton, Dickinson and Company's net margin of 6.44%. Zoetis' return on equity of 51.25% beat Becton, Dickinson and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company6.44% 13.57% 6.56%
Zoetis 27.43%51.25%17.58%

Zoetis received 308 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 77.76% of users gave Zoetis an outperform vote while only 62.25% of users gave Becton, Dickinson and Company an outperform vote.

CompanyUnderperformOutperform
Becton, Dickinson and CompanyOutperform Votes
587
62.25%
Underperform Votes
356
37.75%
ZoetisOutperform Votes
895
77.76%
Underperform Votes
256
22.24%

Summary

Zoetis beats Becton, Dickinson and Company on 15 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDX vs. The Competition

MetricBecton, Dickinson and CompanySurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$66.58B$3.80B$4.98B$17.41B
Dividend Yield1.62%2.15%2.98%3.53%
P/E Ratio54.6113.76207.6023.12
Price / Sales3.4458.162,352.2910.35
Price / Cash11.5943.0847.2117.79
Price / Book2.594.124.604.90
Net Income$1.48B$4.42M$102.97M$964.96M
7 Day Performance-1.15%-1.40%-0.51%1.78%
1 Month Performance-4.63%-7.02%-5.99%-2.48%
1 Year Performance-11.67%14.66%8.89%91.38%

Becton, Dickinson and Company Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZTS
Zoetis
4.9378 of 5 stars
$149.56
+2.8%
$218.00
+45.8%
-11.4%$68.40B$8.54B29.5014,100Upcoming Earnings
Analyst Report
MCK
McKesson
4.8522 of 5 stars
$531.87
+0.9%
$533.50
+0.3%
+48.6%$69.89B$276.71B24.1051,000Dividend Announcement
Analyst Upgrade
Analyst Revision
EW
Edwards Lifesciences
4.5209 of 5 stars
$87.73
+0.9%
$91.73
+4.6%
+0.3%$52.81B$6.00B38.1419,800Short Interest ↓
News Coverage
GILD
Gilead Sciences
4.9992 of 5 stars
$67.03
+0.1%
$84.71
+26.4%
-23.7%$83.46B$27.12B14.9018,000Earnings Report
Analyst Upgrade
Options Volume
Analyst Revision
News Coverage
DXCM
DexCom
4.4943 of 5 stars
$134.00
+1.9%
$141.40
+5.5%
+11.3%$50.70B$3.62B102.299,600Analyst Downgrade
Options Volume
News Coverage
HCA
HCA Healthcare
4.7141 of 5 stars
$319.43
+2.9%
$314.05
-1.7%
+11.4%$84.48B$64.97B16.83310,000
GSK
GSK
2.4091 of 5 stars
$41.24
+1.6%
N/A+10.8%$85.47B$37.71B13.7070,200Upcoming Earnings
Short Interest ↑
COR
Cencora
3.8427 of 5 stars
$237.73
+0.4%
$218.22
-8.2%
+42.6%$47.42B$262.17B25.9046,000Upcoming Earnings
IQV
IQVIA
4.6179 of 5 stars
$238.74
+3.2%
$256.80
+7.6%
+22.1%$43.33B$14.98B32.7587,000Upcoming Earnings
TAK
Takeda Pharmaceutical
0.7122 of 5 stars
$13.39
+0.2%
$14.00
+4.6%
-22.6%$42.36B$29.81B20.2849,095Short Interest ↓
News Coverage

Related Companies and Tools

This page (NYSE:BDX) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners